Literature DB >> 8429530

Therapeutic considerations for preinduction cervical ripening with intracervical prostaglandin E2 gel.

E P Bernstein1.   

Abstract

A commercially prepared prostaglandin E2 (PGE2) gel for cervical ripening has been approved by the U.S. Food and Drug Administration (FDA). In circumstances when labor must be induced before the cervix has undergone spontaneous softening and effacement, this product effectively prepares the cervix for labor. Compared with extemporaneous preparations for vaginal administration, this product offers stability, uniform dosage and minimal side effects. Intracervical PGE2 gel offers significant clinical benefits, but also requires consideration of important clinical issues related to the selection of patients, application of the gel and subsequent monitoring of the patient and fetus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429530

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

Review 1.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 2.  Cost implications in the management of induction of labour.

Authors:  S J Taylor; C L Armour
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.